Enveric Biosciences, Inc.

WHO'M
ai
Digital Profiler. Einfach den AI-Button klicken
CUSIP
29405E208
SEDOL
N/A
CIK
0000890821
www.enveric.com
LEI:
©
FIGI: BBG00P83FXJ0
ENVB
Enveric Biosciences, Inc.
GICS: - · Sektor: Healthcare · Sub-Sektor: Biotechnology
AI
PROFILER
NAME
Enveric Biosciences, Inc.
ISIN
US29405E2081
TICKER
ENVB
MIC
XNAS
REUTERS
ENVB.OQ
BLOOMBERG
ENVB US
BUILD THEMEFOLIO IDEEN TEILEN DISKUTIEREN
HEBEL INVESTIEREN
Financial Intelligence
360° iHub Crowd ATH Tracker Index Tracker ETF TF Spicy X-Billboard
FÜR INVESTOREN
FÜR TRADER
Börsenhandel Warrants
Der X-News Explorer ist die ultimative Informationsquelle für börsenaffine Anleger, die sich schnell und komfortabel einen Überblick über die aktuelle Nachrichtenlage eines börsennotierten Unternehmens verschaffen möchten. Ihnen stehen hier verschiedene Newswire-Services zur Verfügung. Wird ein News-Alert angezeigt, liegen Unternehmensnachrichten vor, die Sie möglicherweise interessieren könnten. Dieser Service wird Ihnen von BusinessWire bereitgestellt.
Do., 06.03.2025       Enveric Biosciences
US29405E2081

Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders, today announced the company will build on its recent business development momentum by soliciting Requests-For-...
weiterlesen
Enveric Biosciences
Research & Analysen Termsheet Terminal
Permalink
Do., 27.02.2025       Enveric Biosciences
US29405E2081

Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders, today announced that Joseph Tucker, Ph.D., CEO and Director, has issued a Letter to Shareholders to provide an...
weiterlesen
Enveric Biosciences
Research & Analysen Termsheet Terminal
Permalink
Di., 25.02.2025       Enveric Biosciences
US29405E2081

Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders, today announced that the United States Patent and Trademark Office issued U.S. Patent No. 12,195,439 (the ‘439...
weiterlesen
Enveric Biosciences
Research & Analysen Termsheet Terminal
Permalink
Di., 04.02.2025       Enveric Biosciences
US29405E2081

Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders, is pleased to announce that its wholly-owned subsidiary, Akos Biosciences, Inc. (“Akos”), has entered into two...
weiterlesen
Enveric Biosciences
Research & Analysen Termsheet Terminal
Permalink
Mo., 03.02.2025       Enveric Biosciences
US29405E2081

Enveric Biosciences, Inc. (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders, today announced the closing of its previously announced public offering of an aggregate of 1,666,666 sha...
weiterlesen
Enveric Biosciences
Research & Analysen Termsheet Terminal
Permalink
Fr., 31.01.2025       Enveric Biosciences
US29405E2081

Enveric Biosciences, Inc. (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders, today announced the pricing of a public offering of an aggregate of 1,666,666 shares of its common stock...
weiterlesen
Enveric Biosciences
Research & Analysen Termsheet Terminal
Permalink
Do., 30.01.2025       Enveric Biosciences
US29405E2081

Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders, today announced that it has received a Notice of Allowance (NOA) from the United States Patent and Trademark O...
weiterlesen
Enveric Biosciences
Research & Analysen Termsheet Terminal
Permalink
Mo., 06.01.2025       Enveric Biosciences
US29405E2081

Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders, today announced Joseph Tucker, Ph.D., CEO, will participate in a panel discussion and present at the Sachs Ass...
weiterlesen
Enveric Biosciences
Research & Analysen Termsheet Terminal
Permalink
Mo., 02.12.2024       Enveric Biosciences
US29405E2081

Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders, today announced that the United States Patent and Trademark Office (USPTO) has issued two U.S. Patents, Nos. 1...
weiterlesen
Enveric Biosciences
Research & Analysen Termsheet Terminal
Permalink
Mo., 25.11.2024       Enveric Biosciences
US29405E2081

Enveric Biosciences, Inc. (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogen small molecule therapeutics for the treatment of depression, anxiety, and other psychiatric disorders, today announced the completion of preclinical pharmacokinetic (“PK”) studies in rat and dog furthe...
weiterlesen
Enveric Biosciences
Research & Analysen Termsheet Terminal
Permalink
We are different
OPEN FINANCIAL
DATA & KNOWLEDGE HUB
We make the difference
Informationen zu Product Placements

 

SMART * AD
EN GIF 970X250

P R O D U C T   S U G G E S T I O N S